Skip to Content

New Drug Approvals Archive - March 2018

See also: New Indications and Dosage Forms for March 2018

March 2018

Trogarzo (ibalizumab-uiyk) Injection

Date of Approval: March 6, 2018
Company: TaiMed Biologics USA Corp.
Treatment for: HIV Infection

Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.

Ilumya (tildrakizumab-asmn) Injection

Date of Approval: March 20, 2018
Company: Sun Pharmaceutical Industries Ltd.
Treatment for: Plaque Psoriasis

Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.

Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Tablets

Date of Approval: March 22, 2018
Company: Mylan N.V.
Treatment for: HIV Infection

Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor (efavirenz), and two nucleo(t)side reverse transcriptase inhibitors (lamivudine and tenofovir disoproxil fumarate) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.